Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): C Noah Nilsson , Mads Kristian Ersbøll , Finn Gustafsson Added: 8 months ago

Heart Failure
Aldosterone and Potassium in Heart Failure
Author(s): Laibah Arshad Khan , Adeena Jamil , Stephen J Greene , et al Added: 5 months ago

Heart Failure

Prevention & Chronic Conditions
Thomas Kahan
Dr Thomas Kahan is Senior consultant in cardiolgy at the Department of cardiology, Danderyd University Hospital Dr Kahan is on the Editorial Board of European Cardiology Review. Research Interests Neurohormonal control of blood pressure and cardiac function in man. Specifically, we study how the sympatho-adrenal mechanisms and the renin-angiotensin-aldosterone system influence… View more
Device-Based Strategies for Guideline-Directed Therapy in Heart Failure
Author(s): Renzo Laborante , Attilio Restivo , Daniela Mele , et al Added: 1 week ago

Heart Failure

Prevention & Chronic Conditions
New Insights on HFpEF Treatment
Author(s): Giulio Balestrieri , Raul Limonta , Enrico Ponti , et al Added: 1 year ago

Guidelines & Statements

Heart Failure
HFA 23: REDWOOD-HCM-Cohort 4: Aficamten in symptomatic nHCM
Author(s): Ahmad Masri Added: 2 years ago
ESC-HFA 23 — We are joined by Dr Ahmad Masri (Oregon Health & Science University Medical Group, US) to discuss the findings from REDWOOD-HCM cohort 4 (NCT04219826). This study assessed the safety and tolerability of the selective inhibitor of cardiac myosin, aficamten (Cytokinetics) in patients with symptomatic nHCM. Cohort 4 included 41 patients. The data presented at HFA 23 shows that… View more

Heart Failure
Mineralocorticoid Receptor Antagonists in Heart Failure
Author(s): Rishi Sethi , Pravesh Vishwakarma , Akshyaya Pradhan Added: 6 months ago

Heart Failure

MI/ACS
Neurohormonal Modulation in HFpEF
Author(s): Vincenzo Castiglione , Francesco Gentile , Nicolò Ghionzoli , et al Added: 1 year ago

Guidelines & Statements

Heart Failure
AHA 24: The REMS Program for Mavacamten
Author(s): Milind Y Desai Added: 6 months ago
AHA Conference 2024 - 22 month data from the risk evaluation and mitigation strategy (REMS) program for mavacamten (Camzyos; Bristol-Myers Squibb Company) in hypertrophic cardiomyopathy (HCM) patients.Dr Milind Desai (Cleveland Clinic, Ohio, US) joins us onsite at AHA Conference to discuss the findings from the REMS program for mavacamten.The REMS program investigated the safety and efficacy of… View more

Heart Failure
2023 ESC Guidelines Update: Acute & Chronic Heart Failure
Author(s): Giuseppe Rosano , Harriette Van Spall Added: 1 year ago
ESC 23 – Late-Breaker host, Dr Harriette Van Spall (McMaster University, CA) is joined by Prof Giuseppe Rosano (St George’s Hospitals NHS Trust University of London, UK), President of HFA to distil the key messages from the 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Prof Rosano summarises the retained ejection fraction… View more

Guidelines & Statements

Heart Failure